GlassScriptPhysician profile
Christine E Kushner
NPI 1548291990
$5,808.13
in general payments reported to CMS, 2019-2025
17 companies · $1,367 in 2025
The $1,367 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,043 · 2022: $2,278 · 2023: $406 · 2024: $714 · 2025: $1,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,487.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $1,186.98 | 2022 | |
| Alkermes, INC. | $1,151.51 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Abbvie INC. | $719.17 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $541.98 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $509.31 | 2021-2025 | Spravato, Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $351.23 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $346.94 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Lundbeck LLC | $289.38 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $146.52 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $135.11 | 2023-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $105.37 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $94.69 | 2022-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $93.57 | 2025 | Uzedy |
| Eisai INC. | $56.49 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $41.38 | 2021-2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $25.50 | 2025 | Fintepla |
| Owp Pharmaceuticals, INC. | $13.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Kushner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.